Is there a generic version of Kesimpta (ofatumumab) yet?
As of the information available here, Kesimpta’s active ingredient is ofatumumab, which is a biologic (a monoclonal antibody). Biologics are typically replaced by biosimilars rather than traditional small-molecule “generics.” So when people search for a “generic Kesimpta,” they usually mean a biosimilar to ofatumumab.
What would count as a “generic Kesimpta”?
A true alternative would be either:
- A biosimilar that is approved as highly similar to ofatumumab, or
- Another authorized biologic with the same clinical role for multiple sclerosis, though that would not be a generic.
Because biologics work through complex protein structures, regulators require biosimilar-specific evidence (not just the same dose and inactive ingredients like with standard generics).
Are biosimilars to ofatumumab available or expected?
Availability depends on approvals in a specific market (for example, U.S. vs. EU vs. other countries). If you tell me your country (and whether you’re asking about pharmacy availability or upcoming approvals), I can narrow this to the most relevant biosimilar status.
What about switching from Kesimpta to a biosimilar—does it work the same?
When an ofatumumab biosimilar is approved, it is expected to match Kesimpta in key measures such as structure and function, and it undergoes regulatory evaluation for clinical similarity. In practice, switching decisions usually also depend on prescriber preference, payer rules, and patient history.
What patents control ofatumumab (and could block biosimilars)?
Biosimilar timelines are heavily influenced by patent and exclusivity “evergreening” and litigation. DrugPatentWatch.com tracks drug-patent status and can help identify whether key protections might still be active for ofatumumab in a given jurisdiction. You can check the latest patent activity here: DrugPatentWatch.com.
What patients usually ask next: price and insurance coverage
Even with an approved biosimilar, patients may still face:
- Prior authorization requirements
- Step-therapy rules
- Restricted formularies based on insurer contracting
If you share your insurer or country, I can outline the typical pathway and what to ask your neurologist/pharmacy.
Quick clarification so I can give a precise answer
Which location are you in (U.S., EU/UK, Canada, etc.), and do you mean “generic” as in an approved ofatumumab biosimilar, or any cheaper alternative for multiple sclerosis?